Abstract: A surfactant-free pharmaceutical composition is described. The composition consists essentially of: (a) a drug component consisting of salbutamol sulphate; and (b) a propellant component consisting essentially of 1,1-difluoroethane (R-152a). A method for preparing the pharmaceutical composition is also described. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml. Another aspect of the invention relates to lipid-complexed platinum compound compositions where the concentration of the platinum compound is greater than about 1.2 mg/ml.

Abstract: Composite materials that are palatable to a wood-destroying pest species and also pesticidal to the pest species can be used in pest control devices and can be used as wood substitutes for structural components, which are resistant to destruction by wood-destroying pests. The composite materials include a thermoplastic polymer, a food material for the pest and a pesticide. The composite material is formed by mixing a thermoplastic polymer, wood fragments or other cellulosic materials and a quantity of pesticide, and thereafter creating a molten material within a mixer, compounder, extruder or the like. The molten material is extruded or molded to form the desired shape.

Abstract: The present invention provides a redispersible powder and aqueous dispersions of nanoparticles of water insoluble organic pesticides. The invention further provides methods for preparing the redispersible powder and the aqueous dispersion, wherein the methods include preparation of an oil-in-water nanoemulsion or microemulsion and solvent removal. The present invention also provides pesticidal compositions of the redispersible powder or aqueous dispersions, and their agricultural use in combating pests.

Abstract: Methods of treating blood disorders are described.

Abstract: The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.

Abstract: A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof as an effective ingredient and an organic acid, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. The method for improving dissolution property and chemical stability of an oral preparation according to the present invention comprises incorporating an organic acid in the oral preparation comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C.

Abstract: Cationic, anionic, and/or zwitterionic bis-urea compounds self-assemble by non-covalent interactions in aqueous solution to form high aspect ratio nanofibers. The nanofibers reversibly bind drugs by non-covalent interactions, forming drug compositions for exhibiting sustained release of the drug.

Abstract: The invention relates to esters of general formula (I) R1—C(?O)—O—R2, wherein (1) R1 represents a linear alkyl radical having 7 to 9 carbon atoms and R2 represents a linear alkyl radical having 9 to 10 carbon atoms or (2) R1 is a linear alk radical having 8 to 9 carbon atoms and R2 is a linear alkyl radical having 8 carbon atoms, or (3) R1 is a linear alkyl radical having 7 to 9 carbon atoms and R2 is a linear alkyl radical having 7 carbon atoms, or (4) R1 is an alkyl radical having 7 or 8 carbon atoms and R2 is an alkyl radical having 9 carbon atoms where, if R1 is a linear alkyl radical, R2 is a branched alkyl radical, or, if R1 is a branched alkyl radical, R2 is a linear alkyl radical or (5) R1 represents an alkyl radical having 8 carbon atoms and R2 is an alkyl radical having 8 carbon atoms, where, if R1 is a linear alkyl radical, R2 is a branched alkyl radical, or, if R1 is a branched alkyl radical, R2 is a linear alkyl radical, or n-octyl isooctanoate, n-decyl isooctanoate, n-decyl isononanoate, isonony

Abstract: This invention related to a cationically and hydrophilically modified polygalactomannan having repeating units with an average D-mannosyl to D-galactosyl residue ratio of at least 5 to 1 and to compositions containing the same. A portion of the hydrogen atoms of hydroxyl groups situated on the mannosyl and galactosyl residues of the galactomannan are replaced with a hydrophilic and a cationic substituent.

Abstract: The present invention relates to a composition for topical application in the form of an oil-in-water emulsion, wherein it contains: a lipophilic phase (A) an emulsifying system (B) an aqueous phase (C), one or more fillers having an oil uptake greater than or equal to 75 ml/100 g, the emulsifying system (B)/lipophilic phase (A) weight ratio ranging from 0.04 to 0.2. This composition is preferably obtained according to the phase inversion (PIT) emulsification technique and it can in particular constitute a cosmetic or dermatological composition.

Abstract: Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose.

Abstract: The present invention pertains to plant additives containing a molecule selected in a family of compounds, wherein said molecule can modulate some molecular markers and physiological modifications observed in cases of phosphate deficiency. The family of compounds comprises the molecule MC2 of formula as well as analogs thereof.

Abstract: The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors.

Abstract: Embodiments of a skin dye protectant formulation comprise at least about 30% by weight of a film forming composition, at least about 40% by weight of a solvent, water, at least 0.1% by weight of a dye, and at least about 1% to about 5% of antioxidants, wherein the formulation is operable to substantially maintain the color of the dye when the skin dye protectant formulation is subjected to gamma sterilization.

Abstract: A plant disease control composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifiuoromethyl group, and one or more dithiocarbamate compounds selected from group (A) consisting of mancozeb, maneb, thiram and zineb is provided by the present invention, and this composition has an excellent effect for controlling a plan disease.

Abstract: Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.

Abstract: Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.

Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, X and Y are as defined herein are inhibitors of glutaminyl cyclase and are therefore useful in treating conditions that can be treated by modulation of glutaminyl cyclase activity.

Abstract: Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.